Recent evidence suggests that the chemokine axis of CXC chemokine ligand-12 and its receptor CXC chemokine receptor-4(CXCL12/CXCR4) is highly expressed in gynecological tumors and the axis of CXC chemokine ligand-16 a...Recent evidence suggests that the chemokine axis of CXC chemokine ligand-12 and its receptor CXC chemokine receptor-4(CXCL12/CXCR4) is highly expressed in gynecological tumors and the axis of CXC chemokine ligand-16 and CXC chemokine receptor-6(CXCL16/CXCR6) is overexpressed in inflammation-associated tumors.This study aimed to determine the relationship between CXCL12/CXCR4,CXCL16/CXCR6 and ovarian carcinoma's clinicopathologic features and prognosis.Accordingly,the expression of these proteins in ovarian tissues was detected by tissue microarray and immunohistochemistry.The expressions of CXCL12/CXCR4 and CXCL16/CXCR6 were significantly higher in epithelial ovarian carcinomas than in normal epithelial ovarian tissues or benign epithelial ovarian tumors.The expression of chemokines CXCL12 and CXCL16 were positively correlated with their receptors CXCR4 and CXCR6 in ovarian carcinoma,respectively(r = 0.300,P < 0.05;r = 0.395,P < 0.05).Moreover,the expression of CXCL12 was related to the occurrence of ascites(χ2 = 4.76,P < 0.05),the expression of CXCR4 was significantly related to lymph node metastasis(χ2 = 4.37,P < 0.05),the expression of CXCR6 was significantly related to lymph node metastasis(χ2 = 7.43,P < 0.05) and histological type(χ2 = 33.48,P < 0.05).In univariate analysis,the expression of CXCR4 and CXCL16 significantly correlated with reduced median survival(χ2 = 4.67,P < 0.05;χ2 = 4.48,P < 0.05).Therefore,we conclude that the chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 may play important roles in the growth,proliferation,invasion,and metastasis of epithelial ovarian carcinoma.展开更多
目的:探讨子宫内膜异位症相关性卵巢癌(EAOC)患者的临床及预后特点。方法:回顾分析2013年1月至2018年9月在南京医科大学附属苏州医院初次诊治的156例卵巢上皮癌患者的临床资料,根据是否伴有内异症分为EM相关性卵巢癌组(EAOC组)和non-EAO...目的:探讨子宫内膜异位症相关性卵巢癌(EAOC)患者的临床及预后特点。方法:回顾分析2013年1月至2018年9月在南京医科大学附属苏州医院初次诊治的156例卵巢上皮癌患者的临床资料,根据是否伴有内异症分为EM相关性卵巢癌组(EAOC组)和non-EAOC组,比较两组的一般资料、临床表现、辅助检查、手术及术后随访资料。结果:与non-EAOC组患者比较,EAOC组患者痛经、扪及包块及阴道不规则出血症状发生率高( P <0.05),剖宫史比例高(21.62% vs 5.04%, P =0.002),并发子宫肌瘤比例高( 35.14% vs 15.97%, P =0.012)。EAOC组和non-EAOC组的血清CA125水平、淋巴结转移比例、FIGO分期分布、肿瘤早期晚期比例比较,差异均有统计学意义( P <0.05)。Kaplan-Meier生存分析发现,EAOC组的中位总生存期、无进展生存期较长( P =0.0256, P = 0.0242 )。结论:与non-EAOC患者比较,EAOC患者的痛经及阴道不规则出血症状较明显,有剖宫产史者较多,更易合并子宫肌瘤,肿瘤分期早,血清CA125水平低,侵犯淋巴结可能性低,预后好。展开更多
目的以Meta分析的方法定量评估HER-2/neu基因扩增/或表达增强状态与上皮性卵巢癌患者手术后的中位生存期和5年生存率的关联性。方法检索、筛选1989年以来所有论述HER-2/neu状态与患者预后关系的中、英文回顾性研究文献。在Ludwig中心符...目的以Meta分析的方法定量评估HER-2/neu基因扩增/或表达增强状态与上皮性卵巢癌患者手术后的中位生存期和5年生存率的关联性。方法检索、筛选1989年以来所有论述HER-2/neu状态与患者预后关系的中、英文回顾性研究文献。在Ludwig中心符号轶(Centered signed rank)和DerSimonian-Laird等方法基础上对各研究提供的生存数据进行统计分析。结果共纳入25篇文献,3251例患者。HER-2/neu表达率为27.1%[95%CI(0,54.8%)],与病理分期、分型和分级无关。HER-2/neu阳性者中位生存期平均减少0.65年,5年生存率下降[HR=1.22,95%CI(1.09,1.36)]。亚组分析显示,HER-2/neu蛋白表达与预后关系最明确,强阳性者5年内死亡风险增加,且对铂类化疗药物的反应性减低。结论在妇科肿瘤临床中,将HER-2/neu作为常规的病理指标使用,有助于进行合理的预后评估,并制定个体化化疗方案。展开更多
基金supported by grants from NationalNatural Science Foundation for Young Scholars of China(No. 30700763)Promotive Research Foundation forExcellent Young and Middle-aged Scientists of Shandong(No. BS2009SW002)
文摘Recent evidence suggests that the chemokine axis of CXC chemokine ligand-12 and its receptor CXC chemokine receptor-4(CXCL12/CXCR4) is highly expressed in gynecological tumors and the axis of CXC chemokine ligand-16 and CXC chemokine receptor-6(CXCL16/CXCR6) is overexpressed in inflammation-associated tumors.This study aimed to determine the relationship between CXCL12/CXCR4,CXCL16/CXCR6 and ovarian carcinoma's clinicopathologic features and prognosis.Accordingly,the expression of these proteins in ovarian tissues was detected by tissue microarray and immunohistochemistry.The expressions of CXCL12/CXCR4 and CXCL16/CXCR6 were significantly higher in epithelial ovarian carcinomas than in normal epithelial ovarian tissues or benign epithelial ovarian tumors.The expression of chemokines CXCL12 and CXCL16 were positively correlated with their receptors CXCR4 and CXCR6 in ovarian carcinoma,respectively(r = 0.300,P < 0.05;r = 0.395,P < 0.05).Moreover,the expression of CXCL12 was related to the occurrence of ascites(χ2 = 4.76,P < 0.05),the expression of CXCR4 was significantly related to lymph node metastasis(χ2 = 4.37,P < 0.05),the expression of CXCR6 was significantly related to lymph node metastasis(χ2 = 7.43,P < 0.05) and histological type(χ2 = 33.48,P < 0.05).In univariate analysis,the expression of CXCR4 and CXCL16 significantly correlated with reduced median survival(χ2 = 4.67,P < 0.05;χ2 = 4.48,P < 0.05).Therefore,we conclude that the chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 may play important roles in the growth,proliferation,invasion,and metastasis of epithelial ovarian carcinoma.
文摘目的:探讨子宫内膜异位症相关性卵巢癌(EAOC)患者的临床及预后特点。方法:回顾分析2013年1月至2018年9月在南京医科大学附属苏州医院初次诊治的156例卵巢上皮癌患者的临床资料,根据是否伴有内异症分为EM相关性卵巢癌组(EAOC组)和non-EAOC组,比较两组的一般资料、临床表现、辅助检查、手术及术后随访资料。结果:与non-EAOC组患者比较,EAOC组患者痛经、扪及包块及阴道不规则出血症状发生率高( P <0.05),剖宫史比例高(21.62% vs 5.04%, P =0.002),并发子宫肌瘤比例高( 35.14% vs 15.97%, P =0.012)。EAOC组和non-EAOC组的血清CA125水平、淋巴结转移比例、FIGO分期分布、肿瘤早期晚期比例比较,差异均有统计学意义( P <0.05)。Kaplan-Meier生存分析发现,EAOC组的中位总生存期、无进展生存期较长( P =0.0256, P = 0.0242 )。结论:与non-EAOC患者比较,EAOC患者的痛经及阴道不规则出血症状较明显,有剖宫产史者较多,更易合并子宫肌瘤,肿瘤分期早,血清CA125水平低,侵犯淋巴结可能性低,预后好。
文摘目的探讨评价血清糖类抗原(carbohydrate antigen,CA)125诊断上皮性卵巢癌(epithelial ovarian cancer,EOC)的意义。方法收集并分析2006年1月1日至2008年12月30日中山大学附属第三医院妇科收治的104例卵巢癌标本。对卵巢癌标本按照国际妇产科联盟(International Federation of Gynecology and Obstetrics,IFGO)对上皮性卵巢癌进行分期。统计学分析血清CA125对卵巢上皮性癌的诊断价值。结果血清CA125>35U/mL诊断上皮性卵巢癌的敏感性和阳性预测值分别是86.2%和83.3%。当血清CA125取值升高时,特异性和阳性预测值增高。上皮性卵巢癌ⅢC期中,细胞低分化组的血清CA125值高于细胞高分化组,差异有显著意义(P<0.05)。血清CA125>150U/mL时,提示晚期卵巢恶性肿瘤的敏感性、特异性和诊断准确性都较好,分别为85.4%、77.3%和78.8%。结论血清CA125在上皮性卵巢癌的组织学分类、细胞分化及和临床分期诊断中具有一定的意义。
文摘目的以Meta分析的方法定量评估HER-2/neu基因扩增/或表达增强状态与上皮性卵巢癌患者手术后的中位生存期和5年生存率的关联性。方法检索、筛选1989年以来所有论述HER-2/neu状态与患者预后关系的中、英文回顾性研究文献。在Ludwig中心符号轶(Centered signed rank)和DerSimonian-Laird等方法基础上对各研究提供的生存数据进行统计分析。结果共纳入25篇文献,3251例患者。HER-2/neu表达率为27.1%[95%CI(0,54.8%)],与病理分期、分型和分级无关。HER-2/neu阳性者中位生存期平均减少0.65年,5年生存率下降[HR=1.22,95%CI(1.09,1.36)]。亚组分析显示,HER-2/neu蛋白表达与预后关系最明确,强阳性者5年内死亡风险增加,且对铂类化疗药物的反应性减低。结论在妇科肿瘤临床中,将HER-2/neu作为常规的病理指标使用,有助于进行合理的预后评估,并制定个体化化疗方案。
